Abstract
Introduction. Hyperbilirubinemia is a common side effect of the antiretroviral agent atazanavir but is generally reversible upon discontinuation of treatment. We used therapeutic drug monitoring to investigate the occurrence of hyperbilirubinemia in a 49-year-old Hispanic man infected with HIV, following an overdose of ritonavir in ritonavir-boosted atazanavir therapy. Case presentation. A 49-year-old Hispanic man with HIV who had received several highly active antiretroviral therapy regimens over a number of years including atazanavir-containing regimens, was diagnosed with hyperbilirubinemia. An inappropriate doubling of ritonavir boosting resulted in a high atazanavir Ctroughand an initial rise in bilirubin plasma levels. Bilirubin levels later decreased, probably as a consequence of enzyme induction, while atazanavir plasma concentrations remained elevated. Conclusion. This article describes an occurrence of hyperbilirubinemia in a man infected with HIV and supports the importance of therapeutic drug monitoring in investigations of hyperbilirubinemia among patients receiving antiretroviral agents. That the patient tolerated exceptionally high atazanavir levels further strengthens the tolerability profile of this drug.
| Original language | English |
|---|---|
| Article number | 9307 |
| Journal | Journal of Medical Case Reports |
| Volume | 3 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Correlations between atazanavir Ctroughand hyperbilirubinemia : A case report. / Uglietti, Alessia; Novati, Stefano; Gulminetti, Roberto; Maserati, Renato.
In: Journal of Medical Case Reports, Vol. 3, 9307, 2009.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Correlations between atazanavir Ctroughand hyperbilirubinemia
T2 - A case report
AU - Uglietti, Alessia
AU - Novati, Stefano
AU - Gulminetti, Roberto
AU - Maserati, Renato
PY - 2009
Y1 - 2009
N2 - Introduction. Hyperbilirubinemia is a common side effect of the antiretroviral agent atazanavir but is generally reversible upon discontinuation of treatment. We used therapeutic drug monitoring to investigate the occurrence of hyperbilirubinemia in a 49-year-old Hispanic man infected with HIV, following an overdose of ritonavir in ritonavir-boosted atazanavir therapy. Case presentation. A 49-year-old Hispanic man with HIV who had received several highly active antiretroviral therapy regimens over a number of years including atazanavir-containing regimens, was diagnosed with hyperbilirubinemia. An inappropriate doubling of ritonavir boosting resulted in a high atazanavir Ctroughand an initial rise in bilirubin plasma levels. Bilirubin levels later decreased, probably as a consequence of enzyme induction, while atazanavir plasma concentrations remained elevated. Conclusion. This article describes an occurrence of hyperbilirubinemia in a man infected with HIV and supports the importance of therapeutic drug monitoring in investigations of hyperbilirubinemia among patients receiving antiretroviral agents. That the patient tolerated exceptionally high atazanavir levels further strengthens the tolerability profile of this drug.
AB - Introduction. Hyperbilirubinemia is a common side effect of the antiretroviral agent atazanavir but is generally reversible upon discontinuation of treatment. We used therapeutic drug monitoring to investigate the occurrence of hyperbilirubinemia in a 49-year-old Hispanic man infected with HIV, following an overdose of ritonavir in ritonavir-boosted atazanavir therapy. Case presentation. A 49-year-old Hispanic man with HIV who had received several highly active antiretroviral therapy regimens over a number of years including atazanavir-containing regimens, was diagnosed with hyperbilirubinemia. An inappropriate doubling of ritonavir boosting resulted in a high atazanavir Ctroughand an initial rise in bilirubin plasma levels. Bilirubin levels later decreased, probably as a consequence of enzyme induction, while atazanavir plasma concentrations remained elevated. Conclusion. This article describes an occurrence of hyperbilirubinemia in a man infected with HIV and supports the importance of therapeutic drug monitoring in investigations of hyperbilirubinemia among patients receiving antiretroviral agents. That the patient tolerated exceptionally high atazanavir levels further strengthens the tolerability profile of this drug.
UR - http://www.scopus.com/inward/record.url?scp=72749106635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72749106635&partnerID=8YFLogxK
U2 - 10.1186/1752-1947-3-9307
DO - 10.1186/1752-1947-3-9307
M3 - Article
C2 - 20062736
AN - SCOPUS:72749106635
VL - 3
JO - Journal of Medical Case Reports
JF - Journal of Medical Case Reports
SN - 1752-1947
M1 - 9307
ER -